Premium
ISTH DIC subcommittee communication on anticoagulation in COVID‐19
Author(s) -
Thachil Jecko,
Juffermans Nicole P.,
Ranucci Marco,
Connors Jean M.,
Warkentin Theodore E.,
Ortel Thomas L.,
Levi Marcel,
Iba Toshiaki,
Levy Jerrold H.
Publication year - 2020
Publication title -
journal of thrombosis and haemostasis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.947
H-Index - 178
eISSN - 1538-7836
pISSN - 1538-7933
DOI - 10.1111/jth.15004
Subject(s) - covid-19 , medicine , intensive care medicine , complication , heparin , coronavirus infections , surgery , pathology , outbreak , disease , infectious disease (medical specialty)
Abstract Hypercoagulability is an increasingly recognized complication of SARS‐CoV‐2 infection. As such, anticoagulation has become part and parcel of comprehensive COVID‐19 management. However, several uncertainties exist in this area, including the appropriate type and dose of heparin. In addition, special patient populations, including those with high body mass index and renal impairment, require special consideration. Although the current evidence is still insufficient, we provide a pragmatic approach to anticoagulation in COVID‐19, but stress the need for further trials in this area.